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CHRONIC LOW INTENSITY CONTINUOUS AND INTERVAL TRAINING 
PREVENT HEART FAILURE-RELATED CORONARY ARTERY STIFFNESS 
 
Heart failure (HF) induced by aortic pressure over-load is associated with 
increased coronary artery stiffness. Perivascular adipose tissue (PVAT) and 
advanced glycation end products (AGE) both promote arterial stiffness. However, 
the mechanisms by which coronary PVAT promotes arterial stiffness and the 
efficacy of exercise to prevent coronary stiffness are unknown. The present study 
hypothesized both chronic continuous and interval exercise training would 
prevent coronary artery stiffness associated with inhibition of PVAT secreted 
AGE and the beneficial effects of interval exercise would be greater than 
continuous exercise.Yucatan mininature swine were divided into four groups: 
control-sedentary (CON), aortic-banded sedentary heart failure (HF), aortic-
banded HF continuous exercise trained (HF+CONT), and aortic-banded HF 
interval exercise trained (HF+IT). Coronary artery stiffness was assessed by ex 
vivo mechanical testing and coronary artery elastin, collagen and AGE-related 
proteins were assessed by immunohistochemistry. HF promoted coronary artery 
stiffness with reduced elastin content and greater AGE accumulation which was 
prevented by chronic continuous and interval exercise training. HF PVAT 
secreted higher AGE compared with CON and was prevented in the HF+CONT 
and HF+IT groups. Young healthy mouse aortas cultured in HF PVAT 
conditioned media had increased stiffness, lower elastin content and AGE 
accumulation compared with CON, which was prevented by PVAT from the 
HF+CONT and HF+IT groups. HF coronary PVAT secreted greater interleukin-6 
(IL-6) and IL-8 compared to CON which was prevented by both continuous and 
interval exercise training regimens. We conclude chronic continuous and interval 
exercise is a potential therapeutic strategy to prevent coronary artery stiffness via 
inhibition of PVAT-derived AGE secretion in a pre-clinical mini-swine model of 
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Stiffening of the large elastic arteries is an independent predictor of 
cardiovascular events, promotes hypertension, and is associated with incident 
heart failure (HF) [1]. HF is defined as dysfunction of ventricular blood filling or 
ejection due to any structural or functional impairment of the heart. [2] The two 
types of HF are HF with reduced ejection fraction (HFrEF) and HF with preserved 
ejection fraction (HFpEF). HFpEF compromises almost 50% of HF patients [2]. In 
addition, no therapy has been shown to improve the survival rate in randomized 
control trial with HFpEF [3]. The increased afterload due to aortic stiffening and 
augmented pulse pressure contributes to the failure of the myocardium [4]. 
Recently, our laboratory reported increased coronary artery stiffness in an aortic-
banded mini-swine model of pressure overload-induced HF [5], indicating the 
increased afterload also promotes coronary vascular dysfunction. Therefore, 
identifying mechanisms and interventions to reduce coronary artery stiffness may 
also alleviate additional stress on an already failing myocardium.  
A key characteristic of arterial stiffening is remodeling of the extracellular 
matrix (ECM) within the vasculature. More specifically, reductions in elastin, 
increased collagen and a greater abundance of advanced glycation end products 
(AGE) collectively promote vascular stiffening [6]. AGE decreases arterial elastin 
and cross-links ECM proteins, in addition to influencing the artery through the 
receptor of AGE (RAGE)-mediated cellular signaling mechanisms [7]. Arterial 
AGE accumulation occurs in conditions where plasma glucose is elevated, such 




shown to secrete AGE [7]. Perivascular adipose tissue (PVAT) is an endocrine 
tissue shown to promote arterial dysfunction, including arterial stiffness [8, 9]. 
These findings are significant as recent evidence has shown PVAT surrounding 
the coronary arteries, which is associated with increased inflammation, predicts 
cardiac mortality [10]. Notably, both aging and HF promote PVAT oxidative stress 
and inflammation, which are important factors for AGE production in adipose 
tissue, suggesting PVAT may be a novel source of AGE contributing to arterial 
stiffness [5, 9, 11]. Currently, however, it is unknown if PVAT secretes AGE to 
promote arterial stiffening with HF. 
Both chronic continuous and interval exercise training programs are 
effective at reducing blood pressure and de-stiffening large elastic arteries such 
as the aorta [12, 13]. However, the influence of exercise training on other conduit 
arteries, such as the carotid artery, is controversial. Continuous exercise training 
for 16-weeks did not decrease carotid artery stiffness in HFpEF patients [14]. 
While 16-weeks interval training prevented carotid artery stiffness of HFpEF mini-
swine [15]. Thus, these data suggest interval exercise training may have greater 
beneficial effects on carotid artery stiffness compared to continuous exercise 
training. However, little is known about the efficacy of chronic continuous and 
interval exercise to prevent coronary artery stiffening in a translational large 
animal HF model.  
The mechanisms by which exercise prevents and/or reverses central 
(aorta and carotid) arterial stiffness have been attributed to maintaining elastin 




inflammation [19]. Importantly, non-exercise interventions that reduce PVAT 
oxidative stress, inflammation and AGE accumulation are associated with 
reductions in aortic stiffness [20]. These findings collectively suggest exercise 
may prevent coronary artery stiffness by lowering PVAT-related AGE secretion.  
The aim of this study was to determine the influence of both chronic 
continuous and interval exercise training on PVAT-related AGE secretion to 
promote coronary artery stiffness in a pre-clinical mini-swine model of pressure 
overload-induced HF. We hypothesize both continuous and interval exercise 
training will prevent coronary artery stiffness associated with ECM remodeling, 
AGE accumulation, oxidative stress and inflammation through a mechanism 
mediated by PVAT-related AGE secretion. We also hypothesize the beneficial 





Review of literature 
 
Cardiovascular disease (CVD) is the leading cause of death in the United 
States and has a serious financial burden on national health care [21-23]. 
According to an American Heart Association (AHA) statement, 40.5% of the U.S. 
population is predicted to have some form of CVD and the medical cost 
estimation is expected to be $818 billion by 2030 [24].  CVD is referred to 
coronary artery disease, atherosclerosis, heart failure, hypertension, arterial 




arterial stiffness is associated with myocardial infarction and stroke which are the 
two leading causes of death in the developed world [27]. Aortic pulse wave 
velocity (aPWV) is the gold standard measurement of arterial stiffness in clinical 
settings. Importantly, aPWV is considered a strong predictor of mortality due to 
cardiovascular-related events and all-cause mortality [28-31]. Thus, it is of great 
importance to understand the mechanisms of arterial stiffness to develop 





The most recent description of arterial stiffness is the reduced buffering 
capacity of arteries which is associated with decreased elasticity of the vascular 
wall [32, 33]. To better explain arterial stiffness, several models have been 
developed [34]. One of them is the Windkessel model [35] which describes the 
arterial system like a fire-hose system. The inverted air-filled dome, referred to 
large artery, was used to buffer the blood flow. The wide-bore hose was the 
conduit vessel. The fire hose nozzle was the peripheral artery/resistance [1]. 
However, elastic artery serves both “conduit” and “cushioning” functions. The 
Windkessel model ignores the “conduit” compliance while only focus on the 
peripheral resistance.  
Artery compliance (C) was first proposed by Spencer and Denison in 1963 
[36]. When given a certain amount of pressure to an artery, the degree of vessel 
volume change is termed as compliance [37]. The compliance can be calculated 




cardiac cycle during systole and diastole. Elastance is the reciprocal of 
compliance. Thus, stiffness can be quantified by elastic modulus/Young’s 
modulus [38]. Compared to the Windkessel model, elastic modulus covers the 
elastic properties (elastin and collagen region) of the arterial wall [1]. Thus, 
arterial stiffness can be also defined as an artery with a reduced capacity to 
expand or recoil during the cardiac cycle. The above explanation of arterial 
stiffness is focused on the arterial wall component alterations, the two primary 
proteins collagen and elastin [39]. However, the factors contributing to arterial 
stiffness are not limited to collagen or elastin.  
 
Measurement of arterial stiffness 
 
Aortic pulse wave velocity (aPWV) 
The aorta is the largest artery that contributes buffering effects to 
modulate blood pressure and maintain consistent blood flow to peripheral ends 
[32, 40-43]. Aortic stiffness affects blood pressure and blood flow. In addition, 
aortic stiffness is an independent predictor of CV events [28, 30, 44-47]. The 
most common and non-invasive clinical measurement of arterial stiffness is aortic 
pulse wave velocity (aPWV), which measures the pulse wave as it travels from 
carotid artery to femoral artery. Currently, pressure sensors (tonometer) which 
captures the wave form from pulse wave is a reliable and reproducible method to 
assess pulse wave velocity [48]. The PWV measurement system detects the time 
delay (Δt) between the feet of the two waveforms and records distance from 




[51]. Normal reference of aPWV value is about 6.2 m/s in less than 30 years old 
population and about 10.9 m/s in older than 70 years old population [52]. 
While aPWV is the gold standard assessment of arterial stiffness, this 
method does have disadvantages. The distance is measured on the body 
surface with a measurement tape by the investigator. In actuality, measured 
distance is an estimation over the true distance and is largely dependent on body 
shape [53]. Thus, systematic error in PWV estimation is dependent on distance 
measurement. To minimize the distance measurement error, some investigators 
recommend: 1) subtracting the distance from the carotid location to the sternal 
notch from the total distance or 2) subtracting the distance from the carotid 
location to the sternal notch from the distance between the sternal notch and the 
femoral site of measurement [50, 54]. In addition, heart rate and blood pressure 
are important confounders of PWV assessment. It has been shown that PWV 
increases with elevated blood pressure and increased heart rates [55, 56]. To 
minimize the blood pressure and heart rate influences, it is recommended that 
measurements be acquired in a quiet room with a minimal resting period of 10 
minutes with no smoking, meals, alcohol, and beverage containing caffeine at 
least 4 hours prior to measurement [54].  
 
Pulse wave analysis 
Pulse wave analysis is a measurement that allows the accurate recording 
of peripheral pressure waveforms and the corresponding central waveform used 




(AtCor Medical, Australia) is one of the most widely used devices to estimate 
central blood pressure which is correlated well with invasive catheter 
measurements of aortic blood pressure [58, 59]. The system can generate 
central hemodynamic parameters: systolic and diastolic pressure, average aortic 
hemodynamic pressure, aortic pulse pressure, augmentation index (AIx) [60]. 
 
Central pulse pressure 
Central pulse pressure is the difference between systolic pressure and 
diastolic pressure which is an important marker of arterial stiffness. Central pulse 
pressure has two determinants: 1) ventricular ejection interacting with the 
viscoelastic properties of the aorta; and 2) wave reflection, or return wave from 
the distal site to heart [32, 61, 62]. Thus, increased arterial stiffness is associated 
with increased central pulse pressure. Increased pulse pressure is also a 
predictor of CV risk in subjects with myocardial infarction and congestive heart 
failure [63-65]. In addition, using pulse pressure to predict the risk of coronary 
heart disease is better than using systolic or diastolic pressure in middle-aged 
and elderly adults [66]. These findings demonstrate the central pulse pressure 
could be an important pathological index in clinical settings. 
 
Augmentation index (AIx) 
AIx is calculated as the difference in height between the first and second 
systolic peaks (augmentation pressure [AP]) in the aortic waveform which is 




determinants of AIx is wave reflection during each cardiac cycle. Wave reflection 
is influenced by three major factors: 1) the distance to the reflecting site; 2) the 
speed of wave transmission, and 3) the magnitude of the reflection coefficient 
[68]. With increased PWV, the reflected wave arrives back to left ventricle earlier 
during diastole. Then the reflection wave leads to a secondary systolic pressure 
peak and increases central pulse pressure [68]. Previous research indicated that 
AIx is correlated with PWV in middle-aged men and women [69]. Thus, AIx could 
potentially serve as a predictor of CV events. As such, AIx is an independent risk 
factor for premature coronary artery disease in young subjects [70]. However, 
previous Framingham Heart Study showed that AIx increased in middle-aged 
individuals and then plateaued (in men) or declined (in women) beyond 60 years 
of age while aPWV continued to increase [71]. Furthermore, AIx was not 
associated with increased aPWV in patients with diabetes and during beta-
adrenergic stimulation [72-74]. Therefore, additional consideration should be 
taken when using AIx as an assessment of arterial stiffness in special population 
groups. 
 
Ex vivo mechanical testing 
Although arteries share the same three layers which are the tunica intima, 
tunica media and tunica external (adventitial), the histological structure and 
composition of the arterial wall differs as does the function. [75]. In human 
beings, vessels more than 10 mm in diameter are typically considered elastic 




percentage of elastic fibers in three layers. The elastic fibers allow the aorta to 
expand or recoil to maintain stable blood pressure and deliver blood to distal 
sites. Arteries with diameters between 0.1mm to 10mm are typically considered 
muscular arteries. Muscular arteries have fewer elastic fibers, which results in 
less ability to expand or recoil, and their major function is to distribute the blood 
to capillaries. Arteries with diameters less than 0.1mm are typically arterioles and 
function to provide resistance. Arterial stiffness assessed by PWV is quite 
different between these different arteries due to differences in wall structural 
components. The human coronary arteries are muscular arteries with an average 
diameter about 4mm, about 10-13 cm in length of the left anterior descending 
artery and 12-14 cm in length of the right coronary artery [76]. Because the 
length of the coronary artery is shorter, errors in assessing distance 
measurement will result in a larger mistake in calculating PWV. Therefore, PWV 
is not an ideal method to assess coronary artery stiffness in vivo. 
The most common and easiest ex vivo mechanical test used to quantify 
arterial stiffness in the laboratory is the uniaxial tensile testing [77]. In this 
procedure an arterial segments are stretched in the horizontal plane at a 
constant displacement rate, while the force generated by artery is recorded. 
Testing is terminated at a yield point when tissue fails to generate force in 
response to increased stretch. The recorded displacement-force data are 
converted to a stress-strain curve. According to Young’s Modulus, stiffness is 
quantified as the slope of the linear part of the stress-strain curve [77]. The toe 




responsible for expansion and recoil of the artery. While the heel part of the 
curve represents the collagen protein effects, which produces force against 
higher pressures. In summary, the most two common arterial stiffness 
assessments are PWV and ex vivo mechanical testing. The advantages of PWV 
are 1) non-invasive, 2) gold standard in clinical settings and 3) predictor of CV 
events. However, it cannot explain the arterial wall structural alterations. The 
advantages of mechanical testing are 1) application to all arteries and 2) 
explanation of the vascular wall component changes, but requires acquisition of 
arterial samples.  
In this research project, the coronary artery stiffness was assessed by ex 
vivo mechanical testing with a Myograph (DMT 620, Denmark). The simplified 




































Importance of arterial stiffness 
Arterial stiffness is a strong predictor of not only CVD-related mortality, but 
also all-cause mortality. Particularly, increased aPWV has been shown as an 
independent predictor of coronary artery disease and stroke over a 10 year 
follow-up [78]. More studies have elucidated the importance of arterial stiffness. 
The estimation of myocardial infarction, unstable angina, heart failure or stroke is 
approximately twice in subjects with higher aPWV compared to subjects with a 
lower aPWV [79]. Another study conducted in well-functioning elders showed that 




[28]. A population-based study also showed that arterial stiffness is strongly 
associated with lipid plaques at various arterial tree sites [80]. An investigation on 
end-stage renal disease patients demonstrated that elevated aortic elastic 
modulus was associated with an increased hazard ratio of cardiovascular and all-
cause mortality [81]. Importantly, angiotensin-converting enzyme inhibitor 
treatment on renal dysfunction patients increased survival rate associated with 
reduced arterial stiffness independent of blood pressure changes [82]. This study 
may suggest that, compared to blood pressure alone, arterial stiffness is more 
tightly related to survival in renal dysfunction patients.  
In general, healthy arteries expand and recoil during systole and diastole. 
The elastic properties of large arteries tends to decrease with aging and disease. 
Prevention strategies and treatments of arterial stiffness are critical to reduce 
CVD-related events and all-cause mortality. Thus, to understand the 
mechanisms of arterial stiffness is essential to support prevention and 
therapeutic strategies to lower CVD risk.  
 
Contributors to arterial stiffness 
Stiff arteries lose the elastic properties which is associated with vascular 
wall remodeling. Arterial stiffness is involved with complicated reactions at the 
cellular and molecular levels. These vasculature alterations are affected by blood 
flow shear force and extrinsic factors such as advanced glycation end products 
(AGE), oxidative stress, inflammatory response and metabolic dysfunctions of 





Collagen and Elastin 
Collagen and elastin are the two major scaffolding proteins which provide 
compliance, elasticity, and stability to the vascular wall [83]. Collagen is the most 
abundant protein in humans and is the main component of connective tissue [84]. 
The most abundant collagen subtypes in the normal human artery are type I (70-
75%), type III (20-25%) and type V (1-2%) [85]. Type I and type III collagens are 
the major components of the three vessel layers, while type IV (comprise more 
than 90% of the total protein of the basal lamina) and type V collagens are in the 
basement membrane of smooth muscle cells of the intima and medial layers [86, 
87]. Elastin is the other major extracellular matrix (ECM) protein of large arteries 
with characteristics of extensibility and elasticity [88]. Elastin formation is limited 
to the embryo stage and infancy [89]. Therefore, elastin content is greatest at 
birth and progressively decreases with aging. Accelerated elastin degradation 
and fragmentation due to some disease conditions will result in premature arterial 
stiffening [90]. 
The production and degradation of collagen and elastin are in balance in 
healthy conditions. Dysregulation of the balance caused by overexpression of 
abnormal collagen and degradation of normal elastin promotes vascular stiffness 
[6]. Increased collagen type I is associated with myocardial fibrosis in 
hypertensive heart disease patients. Another report shows that collagen type I 
overproduction is associated with increased aPWV in diabetes with coronary 




are the major structural component while type IV and type V collagens are not 
[86].  Heart failure induced by hypertension and diabetes has been shown to 
stimulate excessive collagen production [92, 93]. Histological analyses of 
stiffened vessels indicate that the ratio of collagen to elastin was increased [94].  
 
Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs  
Collagen and elastin comprise a large portion of ECM and are regulated 
by matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) [95]. 
MMP are responsible for extracellular matrix degradation. Different MMPs 
subunits have different functions [96]. MMP-1 degrades types I, II, and III 
collagen; MMP-2 degrades type IV collagen and elastin; MMP-3 degrades 
laminin, fibronectin, elastin, gelatin, and proteoglycans, and MMP-9 degrades 
type IV collagen and elastin. A recent publication reported that increased MMP-2 
and 9 levels were greater in hypertensive subjects and positively related to PWV 
[97]. Another study showed that deficiency of MMP-9 and MMP-12 protected 
ApoE -/- mice from atherosclerosis [98]. Moreover, MMP-1 was positively 
correlated with aPWV in both normotensive and hypertensive subjects [99].  
The TIMP family is comprised of four MMP inhibitors: TIMP-1, 2, 3 and 4 
[100]. A human study indicated that plasma TIMP-1 level was increased in 
hypertensive subjects [101]. An animal study demonstrated that hypertension 
induced by angiotensin II was prevented in TIMP 3-/- mice that had reduced 
collagen and elastin content in both the carotid and mesenteric arteries [102]. 




with an adverse remodeling in the extracellular matrix. MMPs expression is also 
regulated by other cellular factors like, increased pro-inflammatory, cytokines, 
and oxidative stress which promote MMPs to induce less effective collagen and 
fragment elastin which in turn promotes vascular stiffness [103-105]. 
 
Advanced glycation end products (AGE) 
Advanced glycation end products (AGE) are complex and heterogeneous 
groups of molecules which are associated with diabetes, cardiovascular disease, 
Alzheimer’s disease and end stage renal disease [7]. 
 
AGE formation  
Reducing sugars react with proteins, lipids, and nucleic acids following 
glycation, oxidation and/or carboxylation to produce AGE [7, 106]. In general, the 
highly reactive glucose aldehyde group with the amino group of proteins produce 
a Schiff’s base, which spontaneously rearranges itself into an Amadori’s product. 
After continued modifications Amadori’s product becomes AGE. In addition, 
some highly reactive carbonyl agents like glyoxal and methyl-glyoxal can be 
produced by oxidized glucose, Schiff’s base and then Amadori’s product will 
react with free amino groups to form N-q-carboxy-methyl-lysine (CML). The slow 
extracellular glycoxidation reaction which produces CML [107] ranges from 
weeks to months, thus long-lived proteins, such as collagen are primary targets 




imidazole (FFI), 1-alkyl-2-formyl-3,4-diglycosyl pyrroles (AFGPs), N-ε-carboxy-
methyl-lysine (CML), pyrraline and pentosidine [109].  
Greater AGE concentrations are usually associated with increased plasma 
glucose and renal dysfunction [7]. AGE concentration was increased after a few 
weeks when animals had increased plasma glucose [110]. Compared to the 
normal conditions, circulating AGE increased approximately two fold in diabetic 
animals [111]. Since small soluble AGE peptides are cleared in the kidney, renal 
dysfunction contributes to AGE accumulation and leads to vascular disease 
[112]. Further, diabetic patients with end stage renal disease (ESRD) had up to 
100 fold circulating AGE compared to diabetics with normal renal function 
patients [113, 114].  
Lipids are involved in the glycation process as well. Quick lipid 
peroxidation with reactive oxygen species (ROS) produces free AGE or protein 
bound AGE in both intracellular and extracellular spaces [115, 116]. AGE 
reduces  paraoxonase activity by 40% in type II diabetes and coronary artery 
disease patients [117] which in turn induces oxidized low-density lipoprotein 
(LDL) accumulation. In our previous study, we found AGE accumulated in the 
aorta with elevated plasma LDL [8]. In addition to the endogenous formation, 
AGE could also be accumulated in blood by food absorption [118, 119]. Plasma 
AGE level is related to aortic stiffness independent of age and blood pressure 
[120]. This finding indicates that adipose tissue is a potential source of AGE.  




The pathogenic influence of AGE are via two different pathways. First, 
AGE form cross-links with proteins that results in an irreversible process which 
alters protein structures and functions [112]. Specifically, AGE cross-linking with 
type I collagen changes the protein structure [121]. AGE can form cross-links 
with collagen IV on the basement membrane to prevent normal network-like 
structures as well [122]. Increased stiffness in the vasculature and other tissues 
due to pathological alterations by AGE-collagen cross-link formation is common 
in diabetic and aging conditions [123]. 
AGE can also form cross-links with LDL through three-dimensional 
structural changes, which in turn, prevented recognition by cellular LDL receptor 
[124]. In addition, excessive AGE increases LDL susceptibility to oxidative 
modifications to promote oxidized LDL formation [125]. The oxidized LDL can 
react with free amino groups of proteins to form AGE products, including CML, 
CEL and others [126, 127].  
In older mice, the increased aortic stiffness has been shown to be 
associated with less elastin per mm2 of the vascular wall by AGE-elastin 
formation [128]. In addition, exogenous AGE administered to rodents promotes 
elastin disruption and fragmentation that is associated with arterial stiffness [129]. 
Previous research has indicated that cross-linking collagen promotes myocardial 
stiffness and cardiac chamber remodeling in hypertensive heart disease. In 
detail, spontaneously hypertensive rats had a decrease in soluble myocardial 
collagen concomitant with an increases in cross-linked myocardial collagen 




conducted on human aorta illustrated a correlation between AGE accumulation 
and aortic stiffness, which is assessed by ex vivo mechanical testing [131-133]. 
Currently, adequate evidence supports the notion that collagen cross-linking is 
an important mechanism of decreased vascular and cardiac compliance.  
Second, AGE binds to a cell membrane receptor to stimulate AGE related 
signaling. AGE have several receptors, the receptor for AGE (RAGE) is the most 
well characterized AGE receptor [134]. RAGE expression is increased in the 
blood and kidneys in those with diabetics compared to control [135]. RAGE has 
also been found on endothelial cells, specifically in the area of atherosclerosis 
[135]. In vitro investigations demonstrated that increased oxidative stress and 
activation of the Nuclear factor-kappa B (NF-κB) signaling was associated with 
AGE-RAGE binding on macrophage cells [136, 137]. We recently reported that 
the greater AGE accumulation in the vascular wall was associated with increased 
oxidative stress and NF-kB p65 subunit expression through RAGE expression 
was unchanged with HF [5].  
AGE has been shown to increase intracellular oxidative stress. A previous 
study indicated that endothelial cells cultured with AGE increased thiobarbituric 
acid reactive substances, a byproduct of lipid peroxidation, and heme oxygenase 
mRNA expression [136]. Moreover, human endothelial cells cultured with AGE 
prompted intracellular generation of hydrogen peroxide and was prevented by 
soluble AGE,  which blocks the RAGE receptor [138]. Further, AGE have been 
shown anti-oxidant properties resulting in a reduction of glutathione, vitamin C 




inflammatory sites and promote atherosclerotic lesions in non-diabetes as well 
[140]. A previous study showed that activated NF-kB induced by AGE released 
interleukin-1 (IL-1), IL-6 and TNF-a [141], in which IL-6 has been shown as a 
contributing factor to aortic stiffness [8]. Moreover, the AGE–RAGE mediated 
cellular signaling includes multiple intracellular signal transduction pathways like 
p21ras, mitogen-activated protein (MAP) kinases, Phosphoinositide 3 (PI3) 
kinase, cdc42/rac, Jak/STAT, NAD(P)H oxidase [138, 139, 142-146] 
In summary, excessive AGE accumulation increases oxidative stress and 
inflammatory response leading to arterial stiffness, while the pathological 
changes are accelerated in diabetic and aging conditions [147]. 
 
Treatment targeting AGE 
Therapeutic interventions focused on AGE formation, AGE cross-linking 
and AGE–RAGE interaction have been investigated. Aminoguanidine (AMG) is 
the first AGE inhibitor which functioned as nucleophilic hydrazine compound to 
prevent Amadori's products that react with proteins to form AGE [148]. AMG 
prevented albumin to form AGE with glucose and AGE cross-linking of collagen 
[148]. Evidence also demonstrated that AMG preserved arterial elasticity through 
inhibition of collagen cross-linking [149]. Further, AMG is the most promising 
agent which reduces the heart AGE levels, RAGE levels and collagen expression 
[150]. In addition, AMG reduces AGE accumulation absorbed from food [151]. 
 Another agent was developed to remove the irreversibly bound AGE from 




is a cross-link breaker compound which has been shown to decrease pulse 
pressure in elderly adults with vascular stiffening [153]. ALT-711 decreased large 
artery stiffness that was associated with reduced collagen deposition and 
attenuates left ventricle stiffness in diabetic and aging animal models [154, 155]. 
The development of AGE cross-link breakers may be a potential target for future 
therapy of isolated systolic hypertension and diastolic heart failure [123]. 
As mentioned above, AGE-RAGE mediated downstream cellular signaling 
promotes oxidative stress and inflammatory responses. This may suggest that 
interference with the AGE-RAGE interaction would interrupt or stop related 
cellular activation, and consequently ameliorate various chronic disorders [156, 
157]. RAGE mRNA has two major truncated forms: N-terminal and C-terminal 
[158] which are named soluble RAGE. Soluble RAGE has been reported to 
dramatically reduce AGE accumulation and improve vascular function [159]. In 
addition, the administration of soluble RAGE to diabetic mice showed that 
inflammatory cells, mRNA levels of glomerular cytokines and extracellular matrix 
were decreased, which in turn reduced vascular lesion area and complexity [160, 
161].  
Insulin has also been proposed to contribute in AGE elimination through 
PI3-kinase pathway associated with nitric oxide production and resulting in 
vascular protective effects [162, 163]. This finding suggests activation of PI3-
kinase not only promotes glucose metabolism but also AGE metabolism. In 
addition, the anti-oxidant agents Vitamin C, has been reported to prevent the 




In summary AGE and AGE-mediated cellular signaling promote 
vasculature dysfunction and wall remodeling through cross-linking formation, 
oxidative stress, and inflammation. Comprehensive understanding of the 
mechanisms of AGE formation and regulated activity is critical to control or 
prevent cardiovascular disease.  
 
Oxidative stress 
Oxidative stress source 
Oxidative stress is an imbalance between the overproduction of reactive 
oxygen species (ROS) and reduced antioxidant defenses [165, 166]. ROS are 
reactive chemicals with oxygen such as peroxides, superoxide, hydroxyl radical 
and single oxygen [167]. The major source of ROS comes from mitochondria 
where oxygen leaks during oxidative phosphorylation [168]. Mitochondrial DNA 
damage is greater in atherosclerotic human arteries compared to normal human 
arteries, in part, due to oxidative stress [169]. Mitochondrial DNA encodes 
portions of the electron transport chain [170], thus damage on mitochondrial DNA 
may cause more ROS leaking from mitochondria associated with structural 
damage. Mitochondria ROS are also regulated by mitochondria membrane 
potential, O2 concentration, nuclear transcription factors, and cytokines [171].  
Peroxynitrite is another ROS compound resulting from the reaction of 
superoxide and nitric oxide along with increased oxidative stress [172]. 
Peroxynitrite oxidizes lipoproteins and nitrate tyrosine residues in many proteins 




proteins have been considered as an indirect biological marker of oxidative 
stress [174]. Though nitrotyrosine is not detectable in the plasma of normal 
healthy subjects [175], the circulating nitrotyrosine concentrations are detectable 
and associated with cardiovascular disease [176].  
 
Oxidative stress influences on cellular dysfunction 
Increased ROS stimulates a pro-inflammation response and activates NF-
κB related signaling [171, 177]. One previous study indicated that cells treated 
with agents that restored ROS prevents protein kinase C, AGE accumulation and 
NF-kB activation [178]. Activation of NACHT, LRR and PYD domains-containing 
protein 3 (NALP3) will trigger an inflammatory response, which is positively 
regulated by ROS [179, 180]. Recent studies showed that excessive ROS had an 
adverse effects on vascular function associated with cellular protein damage and 
an overall reduction in bioavailable endothelium-derived nitric oxide [181]. 
Moreover, reduced ROS accumulation decreased IL-6 production induced by 
endotoxin lipopolysaccharide [177]. Reduced IL-8 expression is associated with 
ROS inhibition in human aortic endothelial cells in vitro [182]. Several studies 
showed that excessive ROS accelerates atherosclerosis lesion formation. 
Deficiency of SOD2, a mitochondria-specific antioxidant enzyme, in 
apolipoprotein E-/- mice contributes to atherogenesis at arterial branching points 
[169]. Also, oxidative stress has been shown to dramatically increase in aortic-
banded guinea pigs and is reduced by Vitamin E therapy [183]. However, clinical 




mortality compared to the control group [184]. Another long-term study showed 
that neither vitamin E nor vitamin C supplementation reduced risk of major 
cardiovascular events [185].  
Oxidative stress has been shown to mediate collagen and collagen-related 
signaling. One study indicated that oxidative stress mediated the collagen type I 
expression and activation of NF-kB in vitro [186]. Another experiment showed 
that exposure to oxidative stress stimulated MMP expression and influenced the 
vascular remodeling [187].  
Oxidative stress could influence vascular function by endothelial cells. 
Substantial evidence suggests that atherosclerotic lesion formation is associated 
with oxidative stress [188]. Another study shows that high blood glucose 
increases ROS, NF-κB activation, upregulation of endothelial cell adhesion 
molecules intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion 
molecule-1 (VCAM-1), trans-endothelial migration of monocytes, and monocyte-
endothelial adhesion in human coronary artery endothelial cells (140). In 
addition, over expression of thioredoxin-2 (Trx2), a mitochondrial antioxidant 
enzyme, attenuated endothelial function and prevented atherosclerotic lesions in 
ApoE-/- mice, which was associated with decreased oxidative stress and elevated 
NO bioavailability [189]. The above evidence suggests that attenuated oxidative 
stress protects the vasculature.  
In summary, oxidative stress has been recognized as a crucial factor to 
vascular diseases and atherosclerosis development. Long-term studies have 




coronary artery disease patients [190] and is strongly associated with arterial 
stiffness measured by PWV [191]. Thus, it is of importance to investigate the 




Inflammation is part of biological responses to local injury [192]. The 
stimulated inflammatory response produces cytokines such as IL-1β, IL-6, tumor 
necrosis factor-α (TNF-α) [193, 194], and activates the NF-κB pathway [195]. C-
reactive protein (CRP), an inflammation marker, has a direct role in promoting 
inflammatory response on human aortic endothelial cells which is associated with 
reduced antioxidant defense [196, 197]. Previous studies have shown that 
reduction of inflammation (CRP) reduced aPWV [198]. It suggests that CRP 
inhibition may decrease PWV. Moreover, arterial stiffness measured by aPWV is 
associated with inflammation-related signaling such as IL-6, TNF-α and CRP 
[199]. Another in vitro study indicated that inflammation promoted arterial 
stiffness associated with vascular wall remodeling through activated mitogen-
activated protein kinases (MAPK) p38 controlled gene [200]. As mentioned in the 
“Oxidative Stress” section, angiotensin II increase ROS production and 
stimulates MMP expression through the expression of active transforming growth 
factor-β (TGF-β) [201] leading to vascular wall remodeling [202]. Another study 
suggested that macrophage, CD68, angiotensin II related proteins and enzymes 




The pathological alterations with inflammation increased vascular wall thickness 
[203]. Also, monocyte chemoattractant protein-1/C-C chemokine receptor type 2 
(MCP-1/CCR2) pathway has an important role in arterial inflammation to induce 
IL-1 and IL-6 expression [204] which resulted in vascular remodeling and left 
ventricular hypertrophy [205]. MCP-1 induces vascular smooth muscle cell 
proliferation and activates NF-kB signaling [206]. In summary, substantial 
evidence demonstrates that inflammation influences arterial stiffness, suggesting 
treatments targeting reductions in the inflammatory response will prevent arterial 
stiffness. 
 
Perivascular adipose tissue (PVAT) 
PVAT characteristics 
In the past decade, much interest has been focused on adipose tissue, 
which surrounds the blood vessels. Recent investigations have demonstrated 
that PVAT is an endocrine tissue and can transfer signals to adjacent blood 
vessels [207]. There is no fascial layer or elastic lamina between PVAT and the 
vasculature, where PVAT interlaces with the adventitial layer [208, 209]. In 
addition, the vasa vasorum within PVAT proliferates when inflammation and 
injury occurrs [210-212], resulting in the release of mediators from PVAT to the 
vascular system. The vasa vasorum are tiny blood vessels which supply blood to 
the outer layers of the artery [213]. Secretomes from PVAT are different from 




suggest that PVAT may have a unique role in influencing the vasculature [215, 
216].  
 
PVAT and cytokines 
One of the key features of PVAT is regulation of inflammation. Cytokines 
like IL-6, IL-8, leptin, MCP-1, and resistin released from PVAT induces 
endothelial cell dysfunction, increases oxidative stress, and causes smooth 
muscle cell proliferation and migration [217-219]. One recent study demonstrated 
that inflammatory cells were increased in PVAT surrounding the atherosclerotic 
aorta compared to the normal aorta [220]. Other similar studies revealed that 
mRNA and protein concentrations of IL-1β, IL-6, MCP-1, and TNF-α were 
elevated and adiponectin protein level was lower in PVAT diseased coronary 
arteries [221, 222]. Wild type mouse aorta cultured with LDL receptor-/-  PVAT 
which secreted greater IL-6, promoted aortic stiffness [8]. Another animal study 
indicated that IL-8, IL-6 and MCP-1 mRNA level and protein expressions were 
higher in PVAT compared to peri-renal and subcutaneous adipose tissue [208], 
thus confirming PVAT’s specific role in inflammatory responses. Another 
research investigation reported that adrenomedullin which was a vasodilator and 
anti-oxidative peptide was expressed in epicardial adipose tissue [223]. Thus, 
PVAT released pro-inflammatory cytokines may serve as a protective mediator.  
Recent studies reported that epicardial adipose tissue size was positively 
related to coronary artery disease, which was associated with insulin resistance 




is not completely understood. Yudkin et al. proposed a “vasocrine” model in that 
cytokines were directly released from PVAT to the vasculature, and thereby 
regulated vascular function [228]. The above studies proposed that mediators 
from PVAT were directly released into adjacent blood vessels. PVAT has been 
shown to affect smooth muscle cells as well. Animal studies have showed that 
PVAT releases cytokines which stimulated smooth muscle cell proliferation [218]. 
Conditioned media from cultured PVAT of aging and obese rats promotes human 
aortic smooth muscle cell proliferation [229]. In summary, cytokines released 
from PVAT contributes to vasculature modifications, but the mechanism is still 
not understood. 
 
PVAT and oxidative stress 
Another feature of PVAT is promoting oxidative stress. Animal study 
showed that mice with characteristics of metabolic syndrome had mesenteric 
artery remodeling associated with increased superoxide production and NADPH 
oxidase activity in PVAT [230]. A similar study concluded that diet induced obese 
mice had vascular endothelial dysfunction and an increased pro-inflammatory 
response associated with increased oxidative stress in PVAT [231]. To confirm 
that oxidative stress promotes aortic stiffness, PVAT from old mice was 
transplanted into healthy young mice which increased PWV and decreased 
elastic modulus. In addition, the increased stiffness was abolished by 4-Hydroxy-
2,2,6,6-tetramethylpiperidine 1-oxyl (TEMPOL), a superoxide scavenger [232]. In 




important regulator of inflammatory responses and oxidative stress. Thus, PVAT 
may be potential novel therapeutic target for improving coronary artery stiffness. 
 
Hypertension and arterial stiffness  
Blood pressure is an important physiological and pathological predictor of 
cardiovascular events [32]. Previous studies have shown that patients with 
isolated hypertension have higher aPWV [233]. In addition, a large population 
study indicated that higher aortic stiffness was associated with an increased risk 
of incident hypertension [234]. These findings revealed the connection between 
arterial stiffness and hypertension. However, it is controversial which comes first: 
arterial stiffness or hypertension [235]. One theory is that vascular wall stiffness 
precedes elevated blood pressure resulting in hypertension. Obese mice fed a 
diet of high fat and high sucrose showed increased aPWV within 1 to 2 months 
which preceded development of hypertension at 5 months [236]. An alternative 
theory is that elevated blood pressure precedes vascular wall alterations: 
hypertension deteriorates vascular wall pathology changes leading to stiffer 
arteries [237]. This long-term study revealed that hypertension exacerbated 
aortic stiffness. Moreover, individuals with well-controlled blood pressure had 
less progression of arterial stiffening assessed by aPWV than individuals poorly 
controlled blood pressure [238]. Recently, numerous studies investigated the 
cellular and molecular mechanisms of arterial stiffening and its relationship with 
the development of hypertension. The elastin knockout (Eln−/−) mouse model has 




pressure in Eln−/− mouse was about twice that of wild-type, and the aortic 
stiffness was further increased. Eln+/- mouse had increased arterial stiffness by 
postnatal day 7, whereas systolic blood pressure increased until postnatal day 14 
[239].  
Treatments for hypertension have been shown to work for attenuation of 
arterial stiffness. Anti-hypertension drugs targeting the renin-angiotensin system 
and aldosterone have been shown to prevent arterial stiffness associated with 
decreased collagen accumulation [240]. However, isoflavones, compounds with 
antioxidant properties, [241] reduced arterial stiffness associated with 
suppressed vascular cell adhesion molecule-1 level but did not affect blood 
pressure [242]. In summary, it is important to better understand the association of 
arterial stiffness and hypertension. 
 
Aging and arterial stiffness 
Aging is defined as the age-related reduction in physiological functions 
essential for survival and fertility [243]. It is well established that aging is 
associated with increased aortic stiffness [244]. Moreover, age-related changes 
in vascular structure and function increase the risk of CVD [245]. 
 
Age-related metabolic syndrome promotes arterial stiffness 
The risk of acquiring metabolic syndrome components, such as obesity, 
dyslipidemia, insulin resistance, and hyperglycemia, increases with aging. 




arterial stiffness and accelerates the development of hypertension [246-249]. In 
particular, diabetes and dyslipidemia leads to endothelial dysfunction, increased 
oxidative stress and inflammation leading to arterial stiffening [243]. Metabolic 
syndrome also interacts with inflammatory responses [250, 251]. Therefore, 
aging promotes activation of inflammatory responses resulting in increased pro-
inflammatory cytokines, which in turn produces more cytokines, resulting in 
endothelial dysfunction and increased oxidative stress [252]. The increased 
oxidative stress and inflammatory responses collectively contribute to arterial 
stiffening.  
 
Aging increases MMPs expression 
Aging is also associated with over expression of MMPs to promote elastin 
degradation and collagen accumulation [253]. MMP-2 is associated with the 
aging process. Over expression of MMP-2 changes the collagen and elastin 
ratio, and activates TGF-β signaling. Increased MMP-2 expression promotes 
arterial stiffness which was associated with vascular wall remodeling and calcium 
content [254]. Inhibition of MMPs prevented age-related arterial inflammation, 
which was associated with preservation of elastin, reduction of collagen leading 
to prevent high blood pressure [253]. Interestingly, it appears that carotid artery 
properties improve with lessening metabolic syndrome severity which suggest 
that arterial stiffness may be reversible with metabolic syndrome [248].  
 




It is evident that oxidative stress occurs with aging. An animal study 
showed that superoxide production was increased in the mesenteric artery in 
aging rats [255] and NO bioavailability was decreased in aging-related 
hypertensive rats [256]. Moreover, recent studies confirmed that aging-related 
endothelial dysfunction and oxidative stress promotes vascular wall remodeling 
and stiffness [257-259]. Therefore, aging-related oxidative stress promotes 
endothelial dysfunction and activation of inflammatory response leading to 
vascular remodeling [260-263]. 
Aging has been shown to induce aldosterone dysregulation, which 
contributes to aging-related inflammatory response [264]. Thus, these findings 
suggest age-related salt sensitivity may be regulated by inflammation and 
contributes to arterial stiffness. It is well known the nervous system is important 
in regulating peripheral artery resistance and blood pressure. A recent study 
showed increased sympathetic nerve activity in older women contributes to the 
development of hypertension but not in young women [265]. Another paper 
demonstrated that reduced sympathetic baroreflex sensitivity promotes arterial 
stiffness and hypertension in elderly adults [266]. The above findings may 
suggest arterial stiffness in aging may be influenced by the nervous system as 
well.  
 
Aging genetic influences in CV events 
Recent interests have been focused on age-related gene changes in 




extended life span [267]. In mice where the klotho gene is overexpressed, 
oxidative stress and insulin resistance were attenuated [267]. Greater expression 
of klotho gene also reduced blood pressure and restored kidney damage in 
spontaneously hypertensive rats [268]. However, the klotho gene expression 
prevented IL-10 production and superoxide production [268]. To confirm the 
influence of klotho on blood pressure, another research group showed that klotho 
gene deficiency caused salt-sensitive hypertension via CCR2 and MCP-1 [269]. 
Since arterial stiffness and hypertension are influenced by oxidative stress and 
inflammation, it would be logical to predict that anti-aging genes have an 
important role in modulating age-related vascular structural and functional 
alterations. 
 
Genetic base of arterial stiffness 
Arterial stiffness is an independent predictor of cardiovascular mortality 
after adjustment for traditional risk factors like age, sex, and mean blood 
pressure [44, 45, 270]. Moreover, carotid artery stiffness was greater in 
teenagers with a parental history of myocardial infarction or diabetes compared 
to the teenager without such parental history [271]. A similar study showed that 
offspring had increased AIx in families which had a history of hypertension [272]. 
Thus, these findings suggest that genetic factors are a potential factor related to 
arterial stiffness.  
 




Gene mutations in elastin and collagen also contributes to arterial 
stiffness. Genetic research on elastin indicated A allele of the Ser422Gly 
polymorphism, which is A-to-G nucleotide change, was positively associated with 
carotid stiffness [273]. Another study showed genetic mutation of fibrillin-1 is 
associated with large artery stiffening and increased pulse pressure in coronary 
artery disease patients [274]. In addition, MMP-3 genotyping promoted aging-
related aortic stiffness associated with vascular remodeling [275]. Though some 
investigations demonstrated phenotype of some genes promoting arterial 
stiffness, the underlying signaling pathway is not well understood. 
 
Genetic mutation of renin-angiotensin system  
Genotype-phenotype studies focused on the renin-angiotensin system 
showed that angiotensin II type 1 receptor gene polymorphism was correlated 
with aortic stiffness [276]. Another large population research concluded that 
angiotensin II type 1 receptor genotype could influence arterial stiffness in aging 
hypertensive patients [277]. A similar study performed in hypertensive patients 
and genotyped mice showed that angiotensinogen gene is a genetic marker for 
arterial stiffness, whereas in genotyped mice with high concentration of 
angiotensinogen had increased arterial stiffening [278]. These data reinforce that 
renin-angiotensin system is another key factor in arterial stiffness. 
 




Heart failure (HF) is a life-threatening disease [279] affecting about 5.7 
million adults in the United States [280]. The risk of death is about 35% in the first 
year after diagnosis with HF [281]. The most common risk factor of HF is 
coronary artery disease (CAD) [279]. Maintenance of coronary artery function is 
critical because the coronary arteries are responsible in the transport of blood 
and nutrition to heart. From the 2016 American Heart Association annual report, 
more than half of all cardiovascular events in both men and women is due to 
CAD [282]. Moreover, the prevalence of CAD will increase about 18% by 2030 
based on projections [282]. CAD due to HF has been well established. However, 
the influence of HF on coronary artery stiffness is largely unknown  [283]. 
 
Heart failure 
HF is a syndrome which includes symptoms such as: shortness of breath 
at rest and exercise, fatigue, pulmonary congestion and abnormal heart structural 
and functional changes [284]. By 2030 more than 8 million adults will be 
expected to have HF in the United States [280]. HF is the underlying cause of 1 
in 9 deaths [285]. Patients with HF have lower stroke volume and cardiac output, 
which results in overstimulation of the sympathetic nerve system and renin-
angiotensin aldosterone system leading to vasoconstriction, and sodium and fluid 
retention. Elevation of blood pressure and increased afterload cause ventricular 
wall remodeling [286]. A long-term study involving with 5143 subjects concluded 
that hypertensive subjects had a greater risk of HF compared to normotensive 




common risk factor of HF. Given the lack of effective therapies [3], research 
about exercise interventions to treat HF has been popular in recent years.  
 
Coronary artery disease 
Pathology of coronary artery disease (CAD) is an imbalance between 
myocardial oxygen demand and supply due to the narrow or blockage in 
coronary arteries [288]. One possible mechanism is lipid deposits on coronary 
artery which results in artery stiffening or atherosclerosis [289]. CAD contributes 
to more than half of all cardiovascular events in individuals less than 75 years old 
[290]. Additionally, CAD is the underlying cause of one in seven deaths [280]. 
However, the effects of HF induced by increased central pressure, on coronary 
artery stiffness has not been examined. 
 
Physical activity/exercise influences on cardiovascular disease 
Definition 
Physical activity is defined as any bodily movement produced by skeletal 
muscles that results in energy expenditure [291]. Exercise is a subset of physical 
activity that is planned, structured, and repetitive and has as a final or an 
intermediate objective the improvement or maintenance of physical fitness [291].  
 
Physical activity/exercise benefits 
Physical activity is a non-invasive prevention and treatment strategy for 




shown to effectively control body weight, lower cholesterol, decrease blood 
pressure and improve cardiovascular fitness, reduce collagen accumulation [295] 
and suppress inflammatory response [296-300]. It is generally accepted that 
physical activity decreases the risk of cardiovascular disease, diabetes, colon 
and breast cancers [301]. Evidence suggests that physically active individuals 
have lower coronary heart disease risk compared to less physically active 
individuals [302-307]. Physical activity has been reported to reduce and treat 
many atherosclerotic risk factors, such as high blood pressure, insulin resistance, 
high triglyceride concentration and low high-density lipoprotein (HDL) 
concentration [308]. Atherosclerotic lesions progression can be prevented or 
slowed and O2 uptake increased during one year treadmill exercise [309]. A 
meta-analysis report showed that after 12 weeks of exercise subjects had 
increased HDL and decreased LDL [310]. A large population study indicated 
moderate intensity exercise help reduces systolic and diastolic blood pressure 
3.4 and 2.4mmHg respectively [311]. In addition, mean systolic and diastolic 
blood pressure reduction in hypertensive subjects were 7.4 and 5.8mmHg 
respectively and in normotensive subjects were 2.6 and 1.8mmHg respectively. 
These results suggest that moderate intensity exercise decreases high blood 
pressure and serves as an effective therapy for hypertensive patients. Chronic 
moderate exercise has also  been reported to attenuate blood glucose 
concentrations in type II diabetics [312].  
 




It has been shown that 30 minutes of moderate cycling causes acute 
reductions in arterial stiffness [313] and 60 minutes of maximal treadmill exercise 
decreases lower-limb vascular stiffness [314]. Investigators proposed that 
reduction in arterial stiffness was due to exercise-related incremental increases 
of NO production from the vascular endothelium. Twelve weeks of exercise 
training increased superoxide dismutase activity, plasma nitrite and nitrate levels 
leading to decrease oxidative stress with increased vasodilation [315]. However 
another experiment concluded that low intensity cycling which reduced PWV was 
not associated with NO production [316]. Animal microarray results showed that 
aorta prostaglandin receptor, C-type natriuretic peptide and endothelial nitric 
oxide synthase genes were overexpressed with reduced aPWV  after 4 weeks 
treadmill running in rats [317]. These findings suggest that exercise-related 
attenuations of arterial stiffness may be associated with improved endothelial 
function with decreased oxidative stress.  
Furthermore, 3-week moderate exercise reduced carotid and femoral 
artery stiffness in type 2 diabetics with improved insulin resistance [318]. Another 
study indicated nutrition and exercise interventions improved radial artery 
elasticity index with decreased blood glucose, cholesterol and C-reactive protein 
[319]. In summary, it is reasonable to conclude that exercise attenuates arterial 
stiffness with decreased oxidative stress. However, the exercise effects on 
arterial stiffness via reductions in inflammation need further investigation. 
 




Exercise is a treatment for patients with coronary heart disease. Low 
intensity exercise improves endothelial function and is associated with increased 
phosphorylation of endothelial nitric oxide (NO) synthase in coronary artery 
disease patients [320]. Exercise rehabilitation after myocardial infarction helps 
reduce cardiovascular mortality, sudden death and fatal or nonfatal re-infarction 
[321]. Clinical meta-analysis suggests cardiovascular death was lower in 
exercise rehabilitation patients [322]. A large population study shows old (~63 y) 
CAD patients had lower risk of all-cause mortality after 5 years light or moderate-
intensity activity compared to the sedentary control group [323]. Another study 
examining exercise training effects on old or young CAD patients indicates that 
12 weeks moderate-intensity exercise improved both groups’ plasma lipid level, 
indices of obesity and exercise capacity [324]. 
 
Exercise treatment in heart failure 
Exercise is also helpful to treat patients with heart failure. Exercise used to 
be restricted in HF patients due to the fear of sudden cardiac death during 
exercise. Until the past few decades, numerous studies have revealed exercise 
testing and training are safe for heart failure patients [325]. Exercise is beneficial 
for heart failure in several ways. First, exercise helps increase peak oxygen 
uptake between 12% and 31% [326]. Second, exercise improves cardiac output 
[327], increases skeletal muscle mitochondrial size and density [328], and 
attenuates endothelial dysfunction [329]. Third, exercise increases NO synthase 




research indicates that long term moderate-intensity exercise training improves 
chronic HF patients’ quality of life and longevity [330]. Notably, Wisløff et al. 
compared the cardiovascular effects of continuous and interval exercise training 
in heart failure patients [331]. After 12 weeks of training, 3 times per week, 
interval exercise trained subjects had greater aerobic capacity that was 
associated with attenuation of LV remodeling compared to continuous exercise 
trained subjects. Moreover, LV end-diastolic and end-systolic volumes decreased 
with interval 
Training, which was associated with preservation of LV ejection fraction and 
reduced of pro-brain natriuretic peptide. This study suggests interval exercise 
training may have greater beneficial effects compared to continuous exercise 
training in patients with HF. 
 
Mechanisms of exercise effects on arterial stiffness in physiological 
settings 
Low intensity chronic exercise reduces blood pressure and increases 
survivability in HF rats induced by hypertension [332]. In addition, moderate-
intensity exercise reduces myocardial stiffness with reduced cross-linking of 
collagen in older rats [333]. Other animal studies showed that exercise 
interventions reduce carotid artery stiffness [334], attenuate myocardial oxygen 
balance and diastolic function in swine [335] and improve survival rats with HF 
[336]. The underlying mechanisms of exercise on physiological adaption has 




showed that exercise increased mouse circulating endothelial progenitor cells 
and reduced endothelial progenitor cell apoptosis dependent on NO synthesis 
[337]. Another animal research showed 8 weeks moderate treadmill walking 
increased anti-oxidant enzyme activity and prevented lipid oxidation in multiple 
organs [338].  
Exercise has also been shown to prevent inflammatory responses in CVD-
related conditions. Exercise had protective effects in the development of 
atherosclerosis or regression of atherosclerotic lesions [339]. Another study 
indicated that hypertensive women had improvements in immune function, 
reduction of IL-1α, TNF-α and elevation of athero-protective cytokines IL-4 and 
IL-10 after 6 months moderate exercise [19].   
This emerging evidence indicates that exercise is beneficial for apparently 
healthy and patient populations. However, no direct evidence demonstrates the 
influence of exercise on AGE in HF conditions. An animal study conducted in an 
obesity rat showed that exercise prevented AGE accumulation [340], but the 
mechanisms were not examined. 
 
High intensity exercise  
In addition to the beneficial effects of exercise, there are potential risks 
such as injury when performing physical activity and exercise. Risk of injury 
increases with greater volume of exercise [341] and intensity [342]. High intensity 
exercise dramatically increased the risk of sudden cardiac death [343, 344] and 




Previous research has reported that improvements of peak oxygen uptake, left 
ventricle remodeling, left ventricle function and endothelial function were greater 
with high intensity exercise than moderate intensity exercise [347]. But the 
underlying mechanisms remain unknown.  
 
Summary 
In summary, arterial stiffness is an independent risk factor and predictor of 
cardiovascular events and all-cause mortality. Thus, investigating the 
mechanisms of arterial stiffness to establish effective therapeutic interventions is 
clinically significant. AGE and PVAT related oxidative stress, and inflammation 
are potential risk factors for arterial stiffness. However, the influence of PVAT-
derived AGE on arterial stiffness has not been explored. While numerous studies 
focused on arterial stiffness with hypertension, few have assessed arterial 
stiffness in HF model. Moreover, no evidence is available to reveal the 
mechanisms of AGE accumulation with coronary artery dysfunction in non-
diabetic conditions. Regular moderate-intensity physical activity has been 
determined as a useful strategy to attenuate HF and coronary heart disease. 
However, the mechanisms of exercise on AGE and its related signaling in non-
diabetic model are poorly understood. Therefore, it is of great importance to 
verify the efficacy of chronic exercise effects on coronary artery stiffness with 









Aortic Banding and Exercise Training Protocols 
The animals in the present study are the same animals used in recently 
published work from our laboratory in the Journal of the American Heart 
Association [334] and the Journal of Applied Physiology [348, 349].  Left 
ventricular hypertrophy/heart failure was induced by aortic banding for a period of 
24 weeks using methods previously published by our laboratory [334, 335, 350-
352].  Moreover, the animal model showed key characteristics of HFpEF with an 
increased end-diastolic P-V slope, increased lung weight, increased LV 
natriuretic peptide levels, and normal resting ejection fraction [334, 348, 349].  
Male Yucatan mininature swine (29-32 kg; 8 months old) were assigned 
into 4 groups (n=7 for all groups): sedentary control (CON), aortic-banded 
sedentary (HF), aortic-banded chronic continuous exercise trained (HF+CONT) 
and aortic-banded chronic interval exercise trained (HF+IT). Aortic bands were 
placed around the ascending aorta (proximal to the brachiocephalic artery), and 
a systolic transstenotic gradient of ~70 mmHg was established (74±2 , 74±2, and 
72±1 mmHg for HF, HF+IT, and HF+CONT, respectively, P= not significant [NS]) 
under anesthesia using phenylephrine (I.V. 1-3 ug/kg/min) to maintain a distal 
peripheral vascular mean aortic pressure (MAP) of approximately 90 mm Hg (90 
± 1, 91 ± 2, and  89 ± 1 for HF, HF+IT and HF+CONT, respectively, P=NS) at a 
heart rate of 100 beats/min (104 ± 5, 99 ± 8, and  106 ± 5 for HF, HF+IT and 




Transverse aortic constriction (TAC) is the most commonly used approach to 
develop pressure overload induced HF in mice [354]. However, cardiac 
hypertrophy is induced within 48 hours after TAC in mice [355]. This acute 
pathological alteration in the heart induced by pressure overload does not mimic 
the gradual changes of myocardial remodeling. [356]. While the mini-swine 
model of pressure overload-induced HF in this study better represents the human 
HF condition. Moreover, HF mice induced by TAC cannot finish the 17 weeks 
exercise training regimen since the 8 week survival rate is less than 50% [357].  
Animals began chronic exercise training consisting of treadmill running 55 
min/day, 3 days/week, for 17 weeks with gradually increases in intensity using 
the following previously published protocols: continuous exercise 1) a 5 min 
warm up at 1.5 mph; 2) 45 min at 2.5 mph; and 3) a 5 min cool down at 1.5 mph 
[349, 353]; interval exercise 1) a 5-min warm up at 2 mph, 2) six 5-min sessions 
at 3 mph with five 3-min intervals at 4 mph in between, and 3) a 5-min cool down 
at 2 mph [335, 348, 358, 359]. This protocol is based off previous findings in 
young, healthy miniswine that underwent a VO2max test. The VO2max of young 
healthy miniswine is about 60ml/kg/min which is similar to a young, physically fit 
adult male [360]. Due to the aortic banding, the intensity used in the current study 
was set at ~30%-40% of VO2max for the healthy miniswine. These exercise 
training protocols have been used in both healthy and HF miniswine, which has 
shown to preserve left ventricular function and improve coronary micro-circulation 
function [361-364]. A table with summarized animal characteristics is attached for 




once daily, and water was provided ad libitum. All animal protocols were in 
accordance with the “Principles for the Utilization and Care of Vertebrate Animals 
Used in Testing Research and Training” and approved by the University of 



























Table 3- 1. Animal Physiological Characteristics 
 CON HF HF+CONT HF+IT 
BW, kg 46±3 48±2 48±1 49±3 
SBP, mmHg 82±7 103±8* 83±7 82±6 
DBP, mmHg 61±8 80±5 68±4 67±5 
LV SV, ml 66±6 67±4 72±3 74±5 
LV EF, % 64±3 66±3 65±3 65±4 
 
Table 3-1. Animal Physiological Characteristics. Values are Mean±S.E. 
n=7 for each group. CON, sedentary control; HF, aortic-banded heart failure 
sedentary; HF+CONT, aortic-banded heart failure continuous exercise trained; 
HF+IT, aortic-banded heart failure interval exercise trained. BW-body weight; 
SBP-systolic blood pressure; DBP-diastolic BP; LV SV-left ventricular stroke 












Mechanical Stiffness Testing 
Arterial stiffness was assessed as previously described [5, 8, 20, 365]. 
The left circumflex (LCX) and right coronary artery (RCA) were cleaned of the 
surrounding adipose tissue and cut into ~1.5mm segments. The coronary arterial 
ring was placed in a preheated 37C Ca2+ and Mg2+ free phosphate buffered 
saline (PBS) solution in Myograph (DMT 620). The artery segment was stretched 
1mm every 3 minutes until mechanical failure. The elastic modulus was 
calculated from the stress-strain curve as previously described [5, 8, 20, 365]. In 
brief, one-dimensional stress (t) was calculated as: t = λL/2HD, and strain (λ) 
defined as: λ = Δd/d(i), where L = one-dimensional load applied, H = wall 
thickness, D = length of vessel, Δd = change in diameter, and d(i) = initial 
diameter. Coronary diameter and wall thickness were assessed in histological 
sections, and length was measured under a dissecting microscope using 
calipers. The elastic modulus was determined as the greatest r2 value from the 
stress-strain curve as described previously [5]. The elastin region, coinciding with 
the elastin elastic modulus (EEM), was determined as the transition point 
between the toe and heel regions of the stress-strain curve, and collagen region, 
coinciding with the collagen elastic modulus (CEM), was the determined greatest 




Figure 3- 1. Representative of Stress-Strain curve. 
Figure 3-1. Representative of Stress-Strain curve. True stress is plotted on the y-
axis and true strain on the x-axis. Transition point (εT) is determined between the 
toe and heel regions. The elastin elastic modulus (EEM) is the slope of the four 
points prior to εT and the collagen elastic modulus (CEM) is the slope of the last 










Coronary Perivascular Adipose Conditioned Media Experiments   
The conditioned media study was performed as described previously by 
our lab [5, 8, 366]. Briefly, adipose tissue surrounding the coronary artery was 
removed and cultured for 24 hours in Dulbecco's modified Eagle's medium 
(DMEM) containing antibiotics (20mg fat/100μl DMEM) at 37° C and 5% CO2. 
The coronary adipose conditioned media (10% of total volume) was heat 
inactivated by placing in a heat block for 30 minutes at 56° C. Aortas (without the 
surrounding adipose tissue) from young (4-6 month old), wild-type C57BL/6 mice 
(The Jackson Laboratory) were cultured in the coronary conditioned media with 
or without 1 mM AGE inhibitor (aminoguanidine, AMG) for 72 hours at 37° C and 
5% CO2. The conditioned media was changed daily. After treatment, aortic 
stiffness testing was performed. 
 
Immunohistochemistry (IHC)  
IHC was performed by standard procedures as previously described [5, 8]. 
Segments of LCX, RCA and mouse aortas were embedded with optimal cutting 
temperature (O.C.T.) and frozen. Arteries were cross-sectioned (8m) , fixed on 
glass slides with acetone and stained using Dako Envison+ system HRP-DAB kit 
(Agilent). The following primary antibodies were used: collagen (abcam), elastin 
(abcam), AGE (abcam), receptor of AGE (RAGE, abcam), nitrotyrosine (EMD), 
NF-κB p65 (abcam) and scavenger receptor A (SRA, TransGenic) were applied 
on slides separately and incubated at 4C overnight with pre-optimized dilutions 




minutes at room temperature followed diaminobenzidine (DAB) application for 
approximately 2 minutes until appropriate darkness achieved. Coronary PVAT 
was fixed in 4% paraformaldehyde, embedded in paraffin, sectioned in 5m 
thickness. Slides were deparaffinized with xylene and proteinase K was used for 
antigen retrieval. Slides were stained with pre-optimized diluted primary 
antibodies (Table. 3-1). Images were acquired using a Nikon 80i microscope 
using a 4x, 10x and 20x objectives for the swine coronary artery, mouse aorta 
and adipose tissue, respectively. Densitometry analysis was performed by 
ImageJ (NIH) on the medial layer of the artery, and the data are presented as 
relative density in arbitrary units (AU).  




PVAT surrounding coronary arteries was fixed in 4% paraformaldehyde, 




tissue was stained with hematoxylin and eosin using standard procedures [5, 8, 
367]. Digital images were acquired with a Nikon 80i microscope with 20x 
objective lens in an uncompressed tiff format. Adipocyte area (μm2) and diameter 
(μm) were averaged from at least 100 cells from 3 tissue sections for each 
sample using ImageJ (NIH). The data for each sample was averaged, and used 
to calculate the mean for each group. 
 
Enzyme-linked Immunosorbent Assay (ELISA)   
Peri-coronary adipose tissue was removed and cultured in serum-free 
DMEM for 24 h at 37°C and 5% CO2 at a concentration of 20mg fat/100μl. AGE 
concentration in swine coronary perivascular adipose conditioned media was 
assessed by ELISA kit per the manufacturer's protocol (Cell Biolabs).  
 
Cytokine Array 
Cytokines in the peri-coronary adipose conditioned media were assessed 
by Porcine Cytokine Antibody Array Kit (Abcam, ab197479).  Ten cytokines 
targets (IL-1β, IL-4, IL-6, IL-8, IL-10, IL-12, GM-CSF, IFNγ, TGFβ1, TNFα) were 
assessed. However, only IL-6 and IL-8 were detectable. Measurement was 
performed per product’s manual. Array fluorescence signals were scanned by a 
laser scanner equipped with Cy3 wavelength (Typhoon 9500, GE, USA). Dots 
densitometry were analyzed by ImageJ (NIH). The quantitative of cytokines were 






All data analyses were performed with Graphpad Prism 7.0. Group mean 
comparisons for coronary stiffness, IHC analyses, the AGE ELISA and cytokines 
array were analyzed by one-way ANOVA. Coronary PVAT culture studies were 
analyzed by two-way ANOVA. Fisher’s LSD post-hoc analyses were performed 
when appropriate. All data were presented as Mean±S.E. Statistical significance 







LV Remodeling and Function 
A thorough investigation of myocardial remodeling and LV function was 
provided for the same animals used in the current study in recently published 
work from our laboratory in the Journal of Applied Physiology [334, 348, 349].  In 
brief summary, these studies demonstrated the therapeutic efficacy of chronic 
exercise training on coronary vascular, isolated cardiomyocyte, and cognitive 
function in a translational pressure-overload model of heart failure with potential 
relevance to human HF.  Aortic banding caused symptoms of heart failure in the 
HF group including increased lung weight and left ventricular natriuretic peptide 
levels, global concentric hypertrophic remodeling at the gross and cellular level, 
and diastolic dysfunction (increased slope of the end diastolic pressure-volume 
relationship).  Echocardiography and pressure-volume analysis indicated ejection 
fraction, fractional shortening, and stroke volume at rest were normal in HF 
compared with CON animals.  Chronic exercise training had a positive impact at 
both the organ and molecular level in a number of different functional systems 
including isolated cardiomyocyte calcium handling and contractile function, large 
conductance Ca2+-activated K+ (BKCa) channel-mediated coronary vascular 
function, and peripheral arterial stiffness and cognition, and we refer the reader 







Exercise Prevents Coronary Artery Stiffness, ECM Remodeling, Oxidative 
stress and Inflammation 
Compared to CON, the combined EEM of the LCX and RCA was lower in 
HF group (284±28 vs. 444±38 kPa, P<0.05; Figure 4-1A), which was associated 
with reduced medial elastin protein content (P<0.05; Figure 4-1B). No differences 
were observed between the CON and HF groups for either the CEM (9324±1319 
vs. 10563±1272 kPa, P>0.05; Figure 4-1C) or collagen content (P>0.05; Figure 
4-1D). The 16-week HF+CONT and HF+IT exercise training regimens prevented 
the decrease in coronary EEM (474±38 and 511±56 kPa, respectively, P<0.05; 
Figure 4-1A) and elastin content (P<0.05; Figure 1B), without influencing CEM or 

















Figure 4- 1. Coronary artery stiffness and arterial elastin and collagen 
content 














































































5 0 0 0
1 0 0 0 0





















Figure 4-1. Coronary artery stiffness and arterial elastin and collagen content. 
Reduced elastin elastic modulus (EEM) (A) and elastin content (B) in HF swine 
coronary was prevented by exercise training. Collagen elastic modulus (CEM) 
(C) and collagen deposition (D) were not different between groups. (Data are 
Mean  S.E., * vs. all, P<0.05). Representative immunohistochemistry images of 
coronary artery showing medial elastin and collagen. Abbreviation: control 
(CON), heart failure (HF), HF continuous exercise trained (HF+CONT), HF 




















Increased coronary stiffness with HF was associated with greater arterial 
AGE abundance, and increased nitrotyrosine, NF-κB p65 and SRA relative to 
CON (P<0.05; Figure 4-2A, 4-2C-E). Arterial RAGE was lower in HF group 
compared to CON group (P<0.05; Figure 2B). Both HF+CONT and HF+IT 
prevented the increase of AGE, nitrotyrosine, NF-κB p65 and SRA (P<0.05; 
Figure 4-2A, 4-2C-E), and the decrease in RAGE (Figure 4-2B; P<0.05). These 
findings demonstrate that a chronic continuous or interval exercise training 
regimen prevents coronary artery stiffness and vascular wall ECM remodeling in 



















Figure 4- 2. Immunohistochemistry analysis of AGE, RAGE, oxidative 














































































































































Figure 4-2. Immunohistochemistry analysis of AGE, RAGE, oxidative stress and 
inflammation level in coronary artery. Greater AGE (A), nitrotyrosine (C), NF-κB 
p65 (D) and scavenger receptor A (SRA) (E) in HF compared with CON, which 
was attenuated by continuous and interval exercise training. (B) Receptor of 
AGE (RAGE) was lower in HF compared to control, HF+CONT and HF+IT. (Data 
are Mean  S.E., * vs. all, P<0.05. The nitrotyrosine abundance in HF+IT showed 
decreased trending compared to HF, P+0.06). Representative 
immunohistochemistry images of coronary artery showing AGE, RAGE 

































PVAT-related AGE Secretion, Arterial Stiffening and ECM Remodeling are 
Prevented by Exercise Training 
Compared with CON, HF had greater PVAT AGE abundance (P<0.05; 
Figure 4-3A) and concentrations of AGE in PVAT-conditioned media (1.404±0.44 
vs. 0.39±0.07μg/mL, P<0.05; Figure. 4-3B). To determine the influence of PVAT-
derived AGE on arterial stiffness, mouse aortas were cultured with the 
conditioned media and stiffness testing was performed. The EEM was reduced 
after exposure to HF compared with CON PVAT-conditioned media (368±20 vs. 
582±29 kPa, P<0.05; Figure 4-3C). Both HF+CONT and HF+IT exercise 
attenuated or prevented the HF-related AGE accumulation in PVAT (P<0.05; 
figure 4-3A), AGE secretion from PVAT (0.27±0.06 and 0.23±0.04 μg/mL, 
respectively, P<0.05; Figure. 4-3B) and the PVAT-induced reduction in EEM 
(542±58 and 518±22 kPa, respectively, P<0.05; Figure 4-3C). The AGE inhibitor, 
AMG, prevented the PVAT-related reduction in EEM with HF (643±35 kPa, 
P<0.05; Figure 4-3C). AMG also increased the EEM in HF+CONT aortic 











Figure 4- 3. AGE secretion from peri-coronary adipose tissue and PVAT 




































































Figure 4-3. AGE secretion from peri-coronary adipose tissue and PVAT derived 
AGE effects on aortic stiffness. Greater peri-coronary adipose tissue AGE (A) 
accumulation in HF compared with CON, HF+CONT and HF+IT. (B) AGE 
concentration in HF swine coronary PVAT conditioned media was higher 
compared to control and exercise training groups. (C) Exposure to HF swine 
coronary conditioned media increased mouse aortic stiffness and AGE inhibitor, 
AMG prevented the increased aortic stiffness. (Data are Mean  S.E., * vs. all, 
P<0.05; $ vs. same group -AMG, P<0.05.) Abbreviation: control (CON), heart 
failure (HF), HF continuous exercise trained (HF+CONT), HF interval exercise 










Effects of peri-coronary adipose conditioned media on aortic 
extracellular matrix, oxidative stress and inflammatory. 
To determine if coronary PVAT-derived AGE contributes to reductions in 
arterial elastin and AGE accumulation, mouse aortas treated with PVAT 
conditioned media were analyzed. Elastin content was decreased (P<0.05; 
Figure 4-4A) and AGE was increased (P<0.05; Figure 4-4B) after culture in HF-
conditioned media. HF+CONT and HF+IT exercise training regimens preserved 
elastin content and prevented AGE accumulation in arteries cultured in HF 
PVAT-conditioned media (Figure 4-4A, 4-4B; P<0.05). AMG prevented the HF-
induced reductions in arterial elastin (P<0.05; Figure 4-4A) and vascular AGE 
accumulation (P<0.05; Figure 4-4B). Arterial segments treated with AMG had 
lower nitrotyrosine and NF-κB p65 subunit expressions compared with segments 
not treated (P<0.05, main effect of drug; Figure 4-4C, D). Collectively, these data 
indicate AGE associated with PVAT promotes arterial stiffness via reductions in 















Figure 4- 4. Influence of coronary adipose conditioned media on aortic 







































































Figure 4-4. Influence of coronary adipose conditioned media on aortic 
extracellular matrix proteins, oxidative stress and inflammation. The HF coronary 
adipose conditioned media decreased mouse aorta elastin content (A) and 
increased AGE (B) compared to other groups while AMG prevented AGE 
accumulation. (Data are MeanS.E., * vs. all, P<0.05; $ vs. same group -AMG, 
P<0.05). Nitrotyrosine (C) and NF-κB p65 (D) were unchanged after cultured in 
coronary adipose conditioned media, but the AGE inhibitor AMG decreased 
nitrotyrosine and NF-κB p65 level. (Data are MeanS.E., * vs. all, P<0.05; $ vs. 
same group -AMG, P<0.05, two-way ANOVA-Interaction effects). Representative 
immunohistochemistry images of mouse aorta showing medial elastin, AGE 
alterations, nitrotyrosine and NF-κB p65 level. Abbreviation: control (CON), heart 
failure (HF), HF continuous exercise trained (HF+CONT), HF interval exercise 

















Exercise Prevents Coronary PVAT Oxidative Stress, Inflammation and 
Cytokines 
Coronary PVAT nitrotyrosine and NF-κB p65 subunit were increased in 
the HF compared with CON (P<0.05; Figure 4-5A, 5B). No differences were 
observed for coronary PVAT SRA (P>0.05,Figure 4-5C) or RAGE (P>0.05, 
Figure 4-5D) between the CON and HF groups. Both exercise regimens 
prevented the increase in nitrotyrosine (P<0.05; Figure 4-5A). Further, HF+CONT 
prevented NF-κB p65 subunit expression (P<0.05; Figure 4-5B) while reductions 
with HF+IT approached significance (P=0.06; Figure 4-5B). Peri-coronary 
adipose secreted more Interleukin-6 (IL-6) and IL-8 in HF conditioned media 
compared to CON (265.88±30.85 vs. 146.02±30.68 pg/mL; 720.93±212.26 vs. 
297.08±25.60 pg/mL, respectively, P<0.05; Figure 4-5E, F). In addition, both 
continuous and interval exercise training prevented IL-6 (167.74±31.97 and 
180.44±24.11 pg/mL, respectively; P<0.05; Figure 4-5E)  and IL-8 (347.02±59.15 




conditioned media. Other cytokines are not detectable. PVAT cell area or 




Figure 4- 5. Immunohistochemistry analysis of oxidative stress and 

































































































































Figure 4-5. Immunohistochemistry analysis of oxidative stress and 
inflammation in peri-coronary adipose tissue. Greater nitrotyrosine (A) and NF-κB 
p65 (B) in HF was attenuated by exercise training. RAGE (C) and SRA (D) level 
















secretion in HF conditioned media were prevented by HF+CONT and HF+IT. 
(Data are Mean±S.E., * vs. all, P<0.05; $ vs. same group -AMG, P<0.05). (Data 
are MeanS.E., * vs. all, P<0.05). Representative immunohistochemistry images 
of coronary artery showing peri-coronary adipose tissue nitrotyrosine, NF-κB p65, 
SRA and RAGE alterations. Abbreviation: control (CON), heart failure (HF), HF 
continuous exercise trained (HF+CONT), HF interval exercise trained (HF+IT). 
 








 In this study, we examined the efficacy of, and identified a mechanism by 
which, a 16-week continuous or interval exercise training regimen prevents 
coronary artery stiffness in a clinically relevant, pressure overload model of HF. 
The primary findings from this study include: 1) both continuous and interval 
exercise training prevent coronary artery stiffness, which is associated with 
preservation of arterial elastin content, and prevention of arterial AGE 
accumulation; 2) PVAT-related AGE secretion promotes arterial stiffness, which 
was prevented by both exercise interventions; and 3) PVAT is a source of AGE 
secretion contributing to decrements in arterial elastin and AGE accumulation. 
These findings provide preliminary evidence for the efficacy for two unique 
exercise regimens to prevent coronary vascular stiffening with HF, and identify 
PVAT-derived AGE secretion as a novel target to prevent arterial stiffening.  
 
Exercise Training Prevents Coronary Stiffening 
A thorough investigation of cardiac function and coronary micro-circulation 
in the animal model used in current study was demonstrated and published in 
Journal of American Heart Association and Journal of Applied Physiology by our 
team [334, 348, 349]. Briefly, both continuous and interval exercise training 
attenuated HF with decreased lung weight and LV brain natriuretic peptide 
mRNA level. Moreover, both exercise training interventions improved coronary 




A primary finding of the present study is that both chronic continuous and 
interval exercise training prevents coronary artery stiffness associated with 
pressure overload-induced HF. To our knowledge this is the first study 
demonstrating an effect of exercise to prevent coronary artery stiffness and the 
associated ECM remodeling. These findings complement recently published 
work from our group in these same animals that demonstrated chronic exercise 
training also preserved coronary microvascular vasodilatory function via a BKCa 
channel-mediated mechanism [348] and prevented stiffening of the carotid artery 
[334], suggesting exercise can prevent pathological adaptations not only to the 
peripheral vasculature but also to the coronaries all along the vascular tree (i.e. 
both macro- and microvessels) in the presence of chronic pressure overload. 
Aerobic exercise training has been shown to reduce both central (aortic) and 
peripheral conduit artery stiffness in older and diseased adults [368-370], which 
are supported by animal models providing insight to the structural changes by 
which exercise attenuates arterial stiffening [16-18]. Moreover, 12 months Tai Chi 
prevents AGE accumulation in healthy subjects [371] and 12 weeks moderate-
intensity exercise training prevents AGE accumulation in healthy women [372]. 
Similar to these prior studies, our findings demonstrate an effect of exercise to 
preserve elastin content, and prevent AGE accumulation [17, 18, 340, 373]. 
Notably, we extend these findings to demonstrate similar effects for both chronic 
continuous and interval exercise to prevent coronary stiffness and ECM 
remodeling. Our findings are supported by previous investigations demonstrating 




and hypertensive subjects [12, 374]. Due to a lack of effective treatment 
strategies for HF patients [3], our findings lend support for exercise training to 
lower coronary artery stiffness, which in combination with previous observations 
of improved coronary vascular conductance in these same animals [348] implies 
an overall effect of exercise to prevent increases in vascular resistance 
throughout the coronary arterial tree. Importantly, these data also show the 
efficacy of chronic exercise training as a therapeutic option for treating coronary 
vascular dysfunction in a setting of pressure overload-induced heart failure, using 
an intensity tolerable to HF patients.  
 
Prevention of Coronary Artery Stiffness due to Preservation of ECM  
The ECM proteins elastin and collagen are primarily responsible for 
contributing to mechanical stiffness of arteries [83]. Our data indicate HF 
promotes coronary artery stiffness by reducing arterial elastin content, without 
influencing collagen. Prior studies demonstrate other pathological conditions, 
such as obesity and hyperlipidemia, as well as the elastin deficient mouse 
promote arterial stiffness by reducing elastin content and/or function [8, 365, 
375]. As such, the elastin elastic modulus was decreased with HF suggesting 
that in addition to lower elastin content, elastin function is also diminished. This is 
the first time to our knowledge it has been shown chronic continuous and interval 
exercise training programs of an intensity tolerable to HF patients prevents 
decrements in elastin content and function in the coronary vasculature of a pre-




have indicated the potential for this effect in the aorta following exercise training, 
although these protocols used a higher training intensity and frequency 
compared to the current study [17, 18]. 
Coronary artery stiffness mediated by AGE 
In addition to changes in the ECM, we observed greater AGE 
accumulation in the coronary artery of HF animals. Chronically increased plasma 
glucose concentrations is a well-recognized factor contributing to AGE formation. 
It is interesting to note the increase in coronary vascular AGE levels in the 
current study was observed in an experimental setting absent metabolic 
comorbidities. This finding recapitulates recently published observations from our 
laboratory in the same swine model, which we previously attributed to increased 
oxidative stress related to chronic pressure overload [5]. AGE cross-links 
proteins within the arterial wall, which includes elastin and collagen, to promote 
arterial stiffness [123, 376]. Further, exogenous AGE administered to rodents has 
shown to promote elastin disruption and fragmentation that is associated with 
arterial stiffness [129]. Thus, the increased coronary AGE may contribute to the 
reductions in elastin content and impaired functionality observed with HF. Elastin 
content and function were preserved with both continuous and interval exercise 
programs in this study, consistent with prior work related to aortic stiffness in 
aged Fisher 344 rats exercised daily at relatively low intensity [373, 377]. 
Collectively, these data indicate exercise training prevents coronary AGE 
accumulation thereby preserving elastin content and function in a translational 




An important downstream effect of AGE is to signal via RAGE that, in turn, 
contributes to arterial oxidative stress and inflammation. As such, we observed 
an increase in nitrotyrosine abundance, and NF-κB p65 and SRA protein in the 
coronary arteries of HF swine. Oxidative stress and inflammation are important 
signaling mechanisms contributing to aortic stiffness both in animal models of 
aging and disease [20, 365] as well as in older adults [370, 378]. More 
specifically, oxidative stress activates a pro-inflammation response via the NF-κB 
signaling pathway [171, 177] which in turn influences the ECM leading to arterial 
stiffness [379]. Our data suggests AGE accumulation with HF increases 
nitrotyrosine, NF-κB and SRA reducing elastin content and function leading to 
arterial stiffness. In support of the beneficial therapeutic effects of exercise, both 
chronic continuous and interval training prevented pressure overload-induced 
increases in nitrotyrosine, NF-κB and SRA in the coronary arteries, suggesting 
the prevention of AGE accumulation by exercise also precludes the arterial 
oxidative stress and inflammatory response induced by HF.  
 
Coronary PVAT and Arterial Stiffness 
PVAT promotes age- and disease-related arterial stiffening and coronary 
PVAT has been shown to predict cardiac mortality, yet the identification of factors 
secreted from this fat depot still need to be elucidated [10, 380]. Consistent with 
our previous findings, perivascular AGE accumulation was increased in PVAT 
from HF animals [5, 20]. We also demonstrate PVAT from HF swine secretes 




from healthy mice similar to what was observed with the coronary artery. To our 
knowledge, this is the first evidence to demonstrate AGE secretion from coronary 
PVAT in a pre-clinical swine model of pressure overload-induced heart failure, 
revealing a novel source of AGE production. Notably, the current study extends 
our previous observations by demonstrating the mechanistic involvement of 
PVAT-derived AGE in the reduced arterial elastin content and increased AGE 
accumulation in the mouse aorta experiments, providing evidence for this fat 
depot to promote ECM remodeling consistent with what was observed in the 
coronary artery of HF animals. Continuous and interval exercise prevented PVAT 
AGE expression and secretion, as well as the impairments to mouse aortas 
exposed to PVAT-conditioned media from HF animals under our in vitro 
experimental conditions including decreased elastin content, function, and 
increased AGE accumulation. Use of the AGE inhibitor AMG also prevented the 
detrimental impact of PVAT-conditioned media from the HF group on mouse 
aortic stiffness and ECM remodeling, suggesting a mechanistic flux point by 
which chronic exercise training exerts its protective effect on pressure overload-
induced coronary arterial stiffness is by reducing PVAT-related AGE secretion 
and associated inflammation. These findings imply further interrogation of AGE 
inhibition is warranted regarding its potential as a useful therapeutic strategy to 
combat coronary arterial stiffness and dysfunction in heart failure. 
 




While AMG severed as prevention of AGE formation, it will probably not 
be effective in patients with a long history of disease that already resulted in 
extensive tissue AGE accumulation. Combined with previous findings that AMG 
has been shown to prevent age-related arterial stiffness and cardiac hypertrophy 
in the absence of changes in collagen and elastin content [381]. This may 
suggest that the effect of AMG is related to a decrease in the AGE-induced 
cross-linking of the extracellular matrix. Our PVAT study indicates that AMG 
cannot preserve elastin content in CON, HF+CONT and HF+IT groups compared 
to no AMG groups which is similar to previous finding. It would be logical to 
predict that the chronic continuous and interval exercise training prevent the 
arterial stiffness through inhibition of AGE cross-linking ECM. We may conclude 
that arteria collagen is not formed cross-linking with AGE.  
 
Effects of Oxidative Stress and Inflammation on Coronary Artery Stiffness 
In the present study, we observed increased coronary PVAT nitrotyrosine 
and NF-κB in the HF group which is consistent with the hypothesis that AGE 
formed in adipose tissue are a result of increased oxidative stress and 
inflammation [7, 127, 382, 383]. Moreover, the cytokine array results indicated 
that HF promoted coronary PVAT IL-6 and IL-8 secretions. The increased IL-6 
level in conditioned media was similar to our previous findings that in pathological 
conditions PVAT secreted excessive IL-6 which plays a key role in regulation of 
arterial stiffness [6]. Oxidative stress has been shown as a regulator of IL-8 




the PVAT with nitrotyrosine abundance could be a source of IL-8 expression. 
Further NF-kappa B and IL-6 family has been shown to interact with 
transcriptional activation of the IL-8 gene [53]. It would be reasonable to conclude 
that increased oxidative stress and NF-κB in PVAT promoted the cytokines 
secretion which finally result in arterial stiffness. Exercise training prevented the 
HF-related increase in PVAT nitrotyrosine abundance, NF-κB p65 subunit 
expression and cytokines secretions, suggesting these processes may indeed 
promote AGE production in PVAT. It is noteworthy, however, that PVAT-
conditioned media from the HF group did not promote arterial oxidative stress 
and inflammation in the mouse aorta, yet inhibition of AGE did lower normal 
levels of these endpoints on a global fashion across all experimental groups 
suggesting other factors such as IL-6 and IL-8 may promote vascular oxidative 
stress and inflammation. However additional research is needed to verify the 
effects of IL-6 and IL-8 on vascular oxidative stress and inflammation.  
In addition, AGE mediated cellular signaling via oxidative stress and 
inflammation is another factor to contribute arterial stiffness. In the present study 
we observe that increased oxidative stress and inflammation in coronary and 
PVAT which is similar to our previous data in the same animal model [5]. 
Considering that AGE formation in adipose tissue are a result of increased 
oxidative stress and inflammation [5, 51-53]. It would be logical to predict that the 
interaction between AGE and oxidative stress and inflammation are, at least, 
partial key features to promote coronary artery stiffness in HF. We observed that 




inflammation in coronary artery and PVAT which may explain that exercise 
prevent AGE accumulation through inhibition of oxidative stress and 
inflammation.  
 
Limitations and Future Directions 
There are several limitations of the current study. 1) As mentioned above, 
arterial stiffness could be influenced by total elastin and collagen content. AGE 
formed cross-linking could also contribute to stiffening arteries. It is noteworthy to 
discriminate that how the elastin, collagen and cross-link affect the stiffness; 2) in 
the current study we investigated AGE accumulation in coronary arteries and 
PVAT as well as AGE secretion from PVAT. Further we added AGE inhibitor into 
PVAT conditioned media and found that with AGE inhibition the stiffness was 
prevented. With these results we conclude that PVAT secreted AGE is a key 
factor in arterial stiffness. However, it is unknown if we will observe the similar 
results when culturing the healthy artery and fat depot directly with AGE. It is 
noteworthy to run these experiments to elucidate whether HF has the similar 
effects as AGE influences on coronary artery stiffness. In addition, we discussed 
the association between oxidative stress and AGE formation. But we still need 
further investigation to determine the PVAT secreted AGE is formed from 
oxidized lipids; 3) this study has 4 groups: CON, HF, HF+CONT and HF+IT. Due 
to the funding and experiment limitations, CON+CONT and CON+IT are not 




HF+IT, whether there is any differences or changes between CON, CON+CONT 
and CON+IT is unclear;  
and 4) women have lower risk rate of cardiovascular diseases at all ages 
compared to men, however the low estrogen level due to post-menopausal will 
dramatically increase the risk of CV events [384, 385]. It is noteworthy to 
consider the sex difference influences on coronary artery stiffness with heart 
failure. Thus, the future study design is focused on aortic-banding and 
ovariectomy effects on female mini-swine to mimic the HF- and aging-related 
women. Previous findings indicated that 8 weeks exercise preserved endothelial 
function and nitric oxide to reduce arterial calcification in ovariectomized rats 
[386]. This provides support that exercise potentially is a therapeutic strategy for 
after menopause women in cardiovascular diseases.  
 
Perspectives 
The prevalence of HF is expected to increase 46% by 2030 and given the 
lack of effective therapies, our findings suggest that chronic continuous and 
interval exercise training could be a therapeutic strategy for reducing arterial 
stiffness in HF patients [3, 387]. Recently we reported chronic exercise training 
preserved coronary microvascular vasodilatory function [348] and prevented 
carotid artery stiffness [334] in this swine model of pressure overload-induced 
heart failure. Our current data extend these findings demonstrating the efficacy of 
chronic continuous and interval exercise to prevent conduit coronary artery 




through the preservation of elastin function in the coronary artery, which was due 
to reduced PVAT-derived AGE. Thus, our study provides support for chronic 
continuous and interval exercise training as a therapeutic option for HF patients 
at an intensity that is tolerable for this population.  
In summary, we provide novel evidence for chronic continuous and 
interval exercise to preserve normal coronary arterial stiffness associated with 
ECM remodeling in a pre-clinical mini-swine model of pressure overload-induced 
HF. We elucidate that PVAT derived AGE plays a key role in coronary artery 
stiffness associated with vascular wall remodeling, oxidative stress and 
inflammation, which is prevented by chronic continuous and interval exercise. 
Previous findings (Table 5-1) are summarized to demonstrate that continuous 
and interval exercise training improves cardiac and coronary artery function and 
prevents carotid artery stiffness [334, 348, 349].The primary findings (Table 5-2) 
and proposed mechanisms (Figure 5-1) are summarized demonstrating the 
effects of chronic low intensity continuous and interval exercise training to 
prevent coronary artery stiffness with HF via inhibition of PVAT derived AGE. 
Collectively, our data lend support that the therapeutic potential of exercise 
intervention to prevent coronary artery stiffness with tolerable intensity to HF 




Table 5- 1. Continuous and interval exercise training improves cardiac and 
coronary artery functions and prevents carotid artery stiffness in HF 
miniswine induced by aortic-banding 
 CON HF HF+CONT HF+IT 
LV BNP mRNA Normal Increased Attenuated Attenuated 
LV fibrosis area and density Normal Increased Attenuated Attenuated 
LV collagen area Normal Increased Attenuated Attenuated 
Carotid Artery PEM Normal Increased Attenuated Attenuated 
Carotid Stiffness Index Normal Increased Attenuated Attenuated 
CBF Normal Decreased Preserved Preserved 
CVC Normal Decreased Preserved Preserved 
 
Table 5-1. CON, sedentary control; HF, aortic-banded heart failure 
sedentary; HF+CONT, aortic-banded heart failure continuous exercise trained; 
HF+IT, aortic-banded heart failure interval exercise trained; LV BNP-left 
ventricular brain natriuretic peptide; PEM-Peterson elastic modulus; CBF-






Table 5- 2. Continuous and interval exercise training prevents coronary 
artery stiffness with the reduction of PVAT derived AGE 
 CON HF HF+CONT HF+IT 
Coronary EEM, kPa 284±28 444±38* 474±38 511±56 
Coronary CEM 9324±1319 10563±1272 10958±1582 10684±1623 
Coronary Elastin‡  1 0.67 1.057 0.97 
Coronary Collagen‡  1 0.9 1.008 0.95 
Coronary AGE‡ 1 1.66 1.173 1.17 
Coronary 
Nitrotyrosine‡  
1 1.31 1.03 1.09 
Coronary NFkB‡  1 1.33 0.98 1.03 
Coronary PVAT AGE‡  1 1.70 1.29 1.32 
PVAT secreted AGE, 
μg/mL 
0.39±0.07 1.404±0.44* 0.27±0.06 0.23±0.04 
 
Table 5-2. CON, sedentary control; HF, aortic-banded heart failure 
sedentary; HF+CONT, aortic-banded heart failure continuous exercise trained; 
HF+IT, aortic-banded heart failure interval exercise trained; EEM-elastin elastic 
modulus; CEM-collagen elastic modulus; PVAT-perivascular adipose tissue; 






Figure 5- 1. Proposed mechanisms by which HF and exercise training 

















Figure 5-1. CONT-continuous exercise training; IT-interval exercise 
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